Calfactant Sterility in Multiple Doses from Single-Use Vials

Abstract

Spanish

French

BACKGROUND:

Calfactant is an exogenous surfactant used to treat and prevent respiratory distress syndrome in the newborn infant. It is available in single-use preservative-free vials, but contains enough volume to provide multiple doses to small infants.

OBJECTIVE:

To measure the preservation of calfactant sterility at 12- and 24-hour intervals following initial violation of vial contents and to extrapolate cost savings associated with product conservation.

METHODS:

A prospective sterility study was performed using calfactant suspension obtained from vials prescribed for infants who had received their dose in the delivery room or the neonatal intensive care unit (NICU). After initial vial entry, test vials were stored in the NICU pharmacy satellite under refrigeration (temperature range 2.2–7.2 °C). Re-entry of test vials and sample removal was performed 12 and 24 hours after initial entry with an 18- or 20-gauge needle. All samples were removed by a neonatal respiratory therapist and placed into 3-mL latex-free, Leurlok plastic syringes and examined by 3 culture media: MacConkey agar, blood agar, and thioglycollate broth.

RESULTS:

A total of 89 surfactant samples from 45 vials were cultured; 45 at a mean time of 13.36 hours (range 11–41) and 44 at a mean time of 25.8 hours (range 22–60) after initial vial entry. These samples represented the technique of multiple respiratory therapists. All samples were negative for bacterial growth at 24 and 48 hours (β = 0.9).

CONCLUSIONS:

Results from this short-term sterility study represent an initial step in the evaluation of multiple doses of surfactant from a single-use vial. The data suggest that 1–2 re-entries into a vial of calfactant, within 24 hours after the initial breach, can be a safe and economical method of providing more than a single dose of surfactant to infants weighing <1 kg. We encourage each institution to reproduce these findings before applying this concept to their patients.

Keywords

calfactant Infasurf multidose sterility surfactant

Get full access to this article

View all access options for this article.

References

Avery

Mead

. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97: 517–23.

Long

, ed. Surfactant replacement therapy. Clin Perinatol 1993; 20: 4.

Bancalari

Sinclair

. Mechanical ventilation. In: Sinclair

Bracken

, eds. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 200–20.

Kendig

Notter

Cox

Reubens

Davis

Maniscalco

, A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med 1991; 324: 865–71.

Egberts

de Winter

Sedin

. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial. Pediatrics 1993; 92: 768–74.

Kattwinkel

Bloom

Delmore

. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 1993; 92: 90–8.

Walti

Paris-Llado

Breart

Couchard

. Porcine surfactant replacement therapy in newborns of 25–31 weeks' gestation: a randomized, multicenter trial of prophylaxis versus rescue with multiple low doses. The French Collaborative Multicentre Study Group Acta Paediatr 1995; 84: 913–21.

Gortner

Wauer

Hammer

Stock

Heitmann

Reiter

, Early versus late surfactant treatment in preterm infants of 27 to 32 weeks' gestational age: a multicenter controlled clinical trial. Pediatrics 1998; 102: 1153–60.

Hudak

Farrell

Rosenberg

Jung

Auten

Durand

, A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996; 128: 396–406.

10.

Kattwinkel

Bloom

Delmore

Glick

Brown

Lopez

, High- versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome. Pediatrics 2000; 106 (2 pt 1): 282–8.

11.

Dunn

Shennan

Possmayer

. Single- vs. multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome. Pediatrics 1990; 86: 564–71.

12.

Speer

Robertson

Curstedt

Halliday

Compagnone

Gefeller

, Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single vs. multiple doses of Curosurf. Pediatrics 1992; 89: 13–20.

13.

Data on file. Columbus, OH: Ross Products Division, Abbott Laboratories, 1999.

14.

Data on file. St. Louis: Forest Pharmaceuticals, 2002.

15.

The United States pharmacopeia. 25th rev., and the national formulary, 20th ed. Rockville, MD: The United States Pharmacopeial Convention, 2002: 1869–83.

16.

Bozzetti

Bonfanti

Regalie

Calligaris

Cozzaglio

. Catheter sepsis from infusate contamination. Nutr Clin Pract 1990; 5: 156–9.

17.

Band

Naki

. Safety of changing intravenous delivery systems at longer than 24 hour intervals. Ann Intern Med 1979; 91: 173–8.

18.

Miller

Smith

Latiolais

. A comparative evaluation of compounding costs and contamination rates of intravenous admixture systems. Drug Intell Clin Pharm 1971:5: 51–60.

19.

Dolin

Davis

Holland

Turner

. Contamination rates of 3-in-1 total parenteral nutrition in a clinical setting. JPEN J Parenter Enteral Nutr 1987; 1: 403–5.

20.

Ebbert

Farraj

Hwang

. The incidence and clinical significance of intravenous fat emulsion contamination during infusion. JPEN J Parenteral Enteral Nutr 1987; 11: 42–5.

21.

Reiter

. Sterility of intravenous fat emulsion in syringes. Am J Health Syst Pharm 2002; 59: 1857–9.

22.

Asmus

Sherman

Hendeles

. Bronchoconstrictor additives in bronchodilator solutions. J Allergy Clin Immunol 1999; 104 (2 pt 2): S53–60.

23.

Beasley

Fishwick

Miles

Hendeles

. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 1998; 18: 130–9.

24.

Castro-Alcaraz

Greenberg

Bateman

Regan

. Patterns of colonization with ureaplasma urealyticum during neonatal intensive care unit hospitalization of very low birth weight infants and the development of chronic lung disease. Pediatrics 2002; 11: 110:E45–52.

25.

Wang

Ohlsson

Kellner

. Association of ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. J Pediatr 1995; 127: 640–4.

26.

Groneck

Schmale

Soditt

Stutzer

Gotze-Speer

Speer

. Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease. Pediatr Pulmonol 2001; 31: 331–8.

27.

Viscardi

Manimtim

Sun

Duffy

Cassell

. Lung pathology in premature infants with ureaplasma urealyticum infection. Pediatr Dev Pathol 2002; 5: 141–50.

28.

DelMonte

. Cost savings from using a surfactant vial for multiple doses. Presented at: Pediatric Pharmacy Advocacy Group Eleventh Annual Meeting, St. Petersburg, FL, October 2–5, 2002.

29.

McGowan

Foster

Coffin

. Outpatient pediatric blood cultures: time to positivity. Pediatrics 2000; 106 (2 pt 1): 251–5.

30.

Kumar

Qunibi

Neal

Yoxall

. Time to positivity of neonatal blood cultures. Arch Dis Child Fetal Neonatal Ed 2001; 85: F182–6.

31.

Garcia-Prats

Cooper

Schneider

Stager

Hansen

. Rapid detection of microorganisms in blood cultures of newborn infants utilizing an automated blood culture system. Pediatrics 2000; 105 (3 pt 1): 523–7.